Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 18,500 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the transaction, the chief executive officer owned 216,744 shares of the company’s stock, valued at $7,963,174.56. This trade represents a 7.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55.
• On Monday, February 23rd, Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock. The stock was sold at an average price of $41.98, for a total transaction of $710,511.50.

Vera Therapeutics Trading Up 6.7%

NASDAQ VERA opened at $39.15 on Thursday. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 52 week low of $18.76 and a 52 week high of $56.05. The stock has a market capitalization of $2.79 billion, a PE ratio of -7.07 and a beta of 0.96. The firm has a 50 day moving average of $39.63 and a two-hundred day moving average of $40.56.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the business posted ($0.81) EPS. As a group, research analysts expect that Vera Therapeutics, Inc. will post -5.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in Vera Therapeutics in the 3rd quarter valued at $911,000. Hudson Bay Capital Management LP raised its position in Vera Therapeutics by 47.4% in the 3rd quarter. Hudson Bay Capital Management LP now owns 440,591 shares of the company’s stock valued at $12,804,000 after purchasing an additional 141,615 shares during the last quarter. Vanguard Group Inc. raised its position in Vera Therapeutics by 6.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock valued at $92,720,000 after purchasing an additional 189,545 shares during the last quarter. AMI Asset Management Corp purchased a new stake in Vera Therapeutics in the 4th quarter valued at $1,444,000. Finally, Candriam S.C.A. raised its position in Vera Therapeutics by 43.9% in the 3rd quarter. Candriam S.C.A. now owns 427,189 shares of the company’s stock valued at $12,414,000 after purchasing an additional 130,248 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on VERA. HC Wainwright upped their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a report on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.60.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.